Ultragenyx Pharmaceutical (RARE) Advances Gene Therapies, But How Durable Is Its Rare-Disease Strategy? [Yahoo! Finance]
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: Yahoo! Finance
Disease Type Ia, while also reporting Phase 3 success for setrusumab in reducing fractures and improving bone density in Osteogenesis Imperfecta patients. Together, these late-stage gene therapy and rare bone disease results highlight how Ultragenyx is aiming to build a broader, clinically validated rare-disease portfolio. We'll now examine how the DTX401 BLA completion and gene therapy progress may influence Ultragenyx's existing investment narrative and risk profile. These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To be a shareholder in Ultragenyx, you need to believe that its focus on rare diseases can eventually translate a broad pipeline into sustainable, higher-margin revenue. The completion of the DTX401 BLA and strong setrusumab Phase 3 data appear to support the near term regulatory catalyst story, while the biggest risk remains the company's s
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREGlobeNewswire
- Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? [Yahoo! Finance]Yahoo! Finance
- A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update [Yahoo! Finance]Yahoo! Finance
- Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery [Yahoo! Finance]Yahoo! Finance
RARE
Earnings
- 11/4/25 - Miss
RARE
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/2/26 - Form 144
- RARE's page on the SEC website